1
|
Zhu MY, Zhu Y, Chen RR, Zhu LX, Zhu JJ, Li XY, Zhou D, Yang XD, Zheng YL, Xie MX, Sun JN, Huang XB, Li L, Xie WZ, Ye XJ. [CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:100-105. [PMID: 32135624 PMCID: PMC7357943 DOI: 10.3760/cma.j.issn.0253-2727.2020.02.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
目的 分析CD7在初治急性髓系白血病(AML)患者中的表达和预后价值,进一步探讨CD7表达情况与CEBPA突变的相关性,明确其在CEBPA野生型和突变型AML患者中与预后的关系。 方法 回顾性分析2010年1月至2016年12月收治的298例初治AML患者(除外M3亚型)的临床资料,在全部患者以及CEBPA野生型和突变型组中,分别比较CD7阳性(CD7+)和CD7阴性(CD7−)患者的临床特征及预后差异,并联合CD7表达情况和CEBPA突变状态初步建立新的危险分层模型。 结果 在CD7+组中,CEBPA单位点和双位点突变的发生率分别为10.1%和33.9%,显著高于CD7−组(5.3%和4.2%),差异具有统计学意义(P=0.000)。在CEBPA野生型患者中,CD7+组患者相较CD7−组患者完全缓解率低(P=0.001)、复发率高(P=0.023),而两组总生存(OS)期和无病生存(DFS)期差异无统计学意义(P值均>0.05);在CEBPA突变患者中,CD7+组显示有更长的OS期(P=0.019)和DFS期(P=0.010)。根据CD7表达和CEBPA突变与否将AML患者分为三个亚组:CD7+伴CEBPA突变组、CD7−组和CD7+伴CEBPA野生型组。三组患者的3年OS率分别为80.2%、48.0%和30.6%(P<0.001),3年的DFS率分别为74.1%、37.4%和22.2%(P<0.001)。 结论 CD7+组中CEBPA突变率显著高于CD7−组,CD7+在CEBPA野生型组和突变组AML中存在截然相反的预后意义。根据CD7表达情况和CEBPA突变与否建立新的危险分层模型,有助于指导临床个体化治疗。
Collapse
Affiliation(s)
- M Y Zhu
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - Y Zhu
- Department of Hematology, Jinhua Hospital of Traditional Chinese Medicine, Jinhua 321017, China
| | - R R Chen
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - L X Zhu
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - J J Zhu
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - X Y Li
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - D Zhou
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - X D Yang
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - Y L Zheng
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - M X Xie
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - J N Sun
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - X B Huang
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - L Li
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - W Z Xie
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| | - X J Ye
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
| |
Collapse
|
2
|
Kobayashi S, Watanabe E, Ishigaki T, Ohno N, Yuji K, Nakano K, Yamochi T, Watanabe N, Tojo A, Watanabe T, Uchimaru K. Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci 2015; 106:598-603. [PMID: 25703103 PMCID: PMC4452161 DOI: 10.1111/cas.12639] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Revised: 02/04/2015] [Accepted: 02/12/2015] [Indexed: 12/01/2022] Open
Abstract
We previously reported that the cell adhesion molecule 1 (CADM1) versus CD7 plot in flow cytometry reflects disease progression in human T-cell leukemia virus type 1 (HTLV-1) infection. In CD4+ cells from peripheral blood, CADM1−CD7+ (P), CADM1+CD7dim (D) and CADM1+CD7− (N) subpopulations are observed. The D and N subpopulations increase as asymptomatic HTLV-1 carriers (AC) progress to indolent adult T-cell leukemia-lymphoma (ATL) and the N subpopulation then expands in aggressive ATL. In the present study we examined whether the analysis can estimate the risk of developing ATL in advanced AC. Peripheral blood samples from AC (N = 41) and indolent ATL patients (N = 19) were analyzed by flow cytometry using the CADM1 versus CD7 plot for CD4+ cells and inverse long PCR (clonality analysis) of FACS-sorted subpopulations. Almost all AC with a high HTLV-1 proviral load (>4 copies/100 cells) had a CADM1+ (D + N) frequency of >10%. AC with 25% < CADM1+ ≤ 50% contained expanded clones similar to smoldering-type ATL. In many patients in the 25% < CADM1+ ≤ 50% group, the proportion of abnormal lymphocytes was distributed around the 5% line, which divides AC and smoldering-type ATL in Shimoyama's classification. In conclusion, the CADM1 versus CD7 plot is useful for selection of putative high-risk AC. The characteristics of some AC and smoldering ATL are said to be similar; however, long-term follow up is required and the clinical outcome (e.g. rate of transformation) of these cases should be used to determine whether to include them in the same clinical category.
Collapse
Affiliation(s)
- Seiichiro Kobayashi
- Division of Molecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Eri Watanabe
- Laboratory of Diagnostic Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Tomohiro Ishigaki
- Laboratory of Diagnostic Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Nobuhiro Ohno
- Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Koichiro Yuji
- Project Division of International Advanced Medical Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Kazumi Nakano
- Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - Tadanori Yamochi
- Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - Nobukazu Watanabe
- Laboratory of Diagnostic Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Arinobu Tojo
- Division of Molecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.,Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Toshiki Watanabe
- Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - Kaoru Uchimaru
- Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|